Teriparatide 10mg

About Teriparatide 10mg

What is Teriparatide?
Teriparatide is the 1-34 N-terminal fragment of parathyroid hormone — 34 amino acids that contain the full receptor-binding domain required for PTH1R (parathyroid hormone receptor 1) activation. The intact PTH molecule is 84 amino acids, but the first 34 are sufficient for complete biological activity at the receptor. Teriparatide is FDA-approved as Forteo for osteoporosis, and it's mechanistically distinct from every other osteoporosis agent in one critical way: it builds new bone rather than simply preventing bone loss.

The central research interest in teriparatide is the PTH administration paradox. Continuous PTH exposure — as in primary hyperparathyroidism — causes net bone resorption and calcium mobilization. But intermittent teriparatide dosing stimulates bone formation over resorption, resulting in increased bone density and improved bone architecture. The mechanism involves activation of canonical Wnt/beta-catenin signaling in osteoblasts, suppression of sclerostin (an osteocyte-derived Wnt inhibitor), and promotion of osteoblast differentiation and survival while transiently increasing RANKL-mediated osteoclast activity. Understanding exactly how the temporal pattern of PTH1R stimulation determines whether anabolic or catabolic pathways dominate is an active area of bone biology research, and teriparatide is the primary pharmacological tool for these studies.

Mechanism of Action

FAQ

Why does intermittent PTH build bone while continuous PTH breaks it down?

The paradox lies in the kinetics of receptor signaling and downstream gene expression. PTH1R is a GPCR that activates both cAMP/PKA and IP3/calcium pathways. Brief, pulsatile activation (as with once-daily teriparatide dosing) preferentially engages the cAMP pathway and activates Wnt signaling — pathways that promote osteoblast differentiation, survival, and bone formation. Sustained receptor activation (continuous exposure, as in hyperparathyroidism) downregulates cAMP signaling and shifts toward RANKL upregulation in osteoblasts, which recruits and activates osteoclasts (bone-resorbing cells) at a rate that exceeds formation. The same receptor, the same ligand — but timing determines whether net effect is anabolic or catabolic. This is one of the most instructive examples in pharmacology of how temporal dosing patterns fundamentally alter physiological outcomes.

What bone cell types does teriparatide act on?

PTH1R is expressed on osteoblasts (bone-forming cells) and osteocytes (the embedded mature bone cells that coordinate bone remodeling), but not meaningfully on osteoclasts (bone-resorbing cells). Teriparatide's direct effects are on osteoblast lineage cells. In osteoblasts, intermittent PTH1R activation drives Wnt/beta-catenin signaling and suppresses apoptosis, increasing their number and activity. In osteocytes, it suppresses sclerostin expression — sclerostin normally inhibits Wnt signaling in osteoblasts, so reducing it amplifies the anabolic effect. The indirect effects on osteoclasts (via RANKL/OPG changes in osteoblasts) produce a transient increase in resorption that's outweighed by the larger formation response under intermittent dosing conditions.

Research Overview

Specifications

Molecular weight~4,118 Da
SequencePTH residues 1-34 (34 amino acids)
Presentation10mg lyophilized
Purity≥98% HPLC
CAS52232-67-4

Storage
Store at -20°C. Reconstitute in sterile PBS or 0.9% saline; stable at 4°C for 2-3 weeks after reconstitution. The 1-34 fragment is more stable than full-length PTH but benefits from the same cold, light-protected storage conditions applied to other medium-size peptides.

Quality
HPLC purity analysis, mass spec identity confirmation, endotoxin testing on every batch. COA ships with every order. EU-based QC under CERTALAB S.R.L.

Product Specifications

• Purity: 99.3% avg (HPLC verified)
• Form: Lyophilized powder
• SKU: CP-TER10

Certificate of Analysis available for every batch. View COAs →

For research purposes only. Not for human consumption.